Biased agonism at G protein-coupled receptors (GPCRs) has significant implications for current drug discovery, but molecular determinants that govern ligand bias remain largely unknown. The adenosine A 3 GPCR (A 3 AR) is a potential therapeutic target for various conditions, including cancer, inflammation, and ischemia, but for which biased agonism remains largely unexplored. We now report the generation of bias "fingerprints" for prototypical ribose containing A 3 AR agonists and rigidified (N)-methanocarba 59-N-methyluronamide nucleoside derivatives with regard to their ability to mediate different signaling pathways. Relative to the reference prototypical agonist IB-MECA, (N)-methanocarba 59-Nmethyluronamide nucleoside derivatives with significant N 6 or C2 modifications, including elongated aryl-ethynyl groups, exhibited biased agonism. Significant positive correlation was observed between the C2 substituent length (in Å) and bias toward cell survival. Molecular modeling suggests that extended C2 substituents on (N)-methanocarba 59-N-methyluronamide nucleosides promote a progressive outward shift of the A 3 AR transmembrane domain 2, which may contribute to the subset of A 3 AR conformations stabilized on biased agonist binding.
Introduction
The A 3 adenosine receptor (A 3 AR) belongs to the adenosine family of rhodopsin-like G protein-coupled receptors (GPCRs) (Fredholm et al., 2011) . The A 3 AR represents a novel therapeutic target for a number of pathologies (Jacobson and Gao, 2006; Fishman et al., 2012) . Given their clinical potential, significant effort has been invested into identifying potent A 3 AR ligands with high subtype selectivity and minimal species variability (Jacobson et al., 2009; Müller and Jacobson, 2011) . Currently, two A 3 AR agonists, N 6 -(3-iodobenzyl)adenosine-59-N-methyluronamide (IB-MECA) and 2-chloro-N 6 -(3-iodobenzyl)-adenosine-59-N-methyluronamide (Cl-IB-MECA), are in clinical trials for the treatment of psoriasis, rheumatoid arthritis, dry-eye syndrome, and hepatocellular carcinoma (Fishman et al., 2012) .
GPCRs are dynamic proteins that can adopt a spectrum of conformations (Vaidehi and Kenakin, 2010) . Biased agonism results from different agonists stabilizing distinct subsets of GPCR conformations, each associated with their own signaling profile (Kenakin, 2011) . Hallmarks of biased agonism include changes in the relative potency of a set of compounds across different signaling pathways, which can result in a reversal in the rank orders of potency or maximal effects (Urban et al., 2007; Kenakin et al., 2012) . Although relatively unexplored, A 3 AR biased agonism and biased allosteric modulation have been observed at the A 3 AR (Gao and Jacobson, 2008; Gao et al., 2011; Verzijl and IJzerman, 2011) . Previous studies, which profiled structurally distinct A 3 AR ligands in terms of cAMP accumulation and b-arrestin recruitment, identified compounds that differed with respect to their coupling to G protein-dependent and G proteinindependent pathways (Gao and Jacobson, 2008) . For example, whereas the xanthine-7-riboside agonist 1,3-dibutylxanthine-7-riboside-59-N-methylcarboxamide had higher efficacy for cAMP accumulation compared with b-arrestin recruitment, -(3-iodobenzyl)adenosine had no significant effect on cAMP accumulation but were partial agonists for b-arrestin recruitment.
Therapeutically, biased agonism can have significant implications, as different signaling patterns may engender divergent clinical outcomes. A well-documented example of this phenomenon occurs at the angiotensin II receptor type 1 (AT 1 R). AT 1 R antagonists are used for treatment of hypertension but are associated with reduced cardiac output (Violin et al., 2010) . A biased peptide analog of angiotensin, Sar-Arg-Val-Tyr-IleHis-Pro-D-Ala-OH, can reduce blood pressure while improving cardiac output through strong activation of b-arrestin recruitment in the absence of G protein signal transduction (Violin et al., 2010; Boerrigter et al., 2011) . This example highlights the importance of understanding intracellular signaling profiles to both retrospectively and prospectively predict the clinical efficacy of a compound.
The structure-activity relationship (SAR) of A 3 AR agonists has been investigated extensively (Jacobson et al., 2009) . The affinity and/or subtype selectivity of A 3 AR agonists can be enhanced through substitution of the ribose tetrahydrofuryl group with a rigid bicyclo[3.1.0]hexane (methanocarba) ring system, the addition of m-substituted benzyl groups at the N 6 position, or the addition of alkyn-2-yl groups to the C2 position (Kim et al., 1994; Jacobson et al., 2000; Volpini et al., 2009; Tosh et al., 2012a) . The North (N)-methanocarba ring system maintains conformation of the ribose ring that is favored at the A 3 AR. Furthermore, the subtype selectivity of A 3 AR agonists can be enhanced through 59-N-methyluronamide substitution (Tosh et al., 2012b) . Collectively, these studies provide a valuable framework, particularly with respect to the N 6 and C2 position, for the rational design of potent A 3 AR agonists with high efficacy and subtype selectivity. However, a limitation of many A 3 AR SAR studies is that agonist potency has been defined using a single assay of receptor function. Such an approach is used routinely within drug discovery to rapidly screen and rank compound libraries according to potency but is limited with respect to identification of the full spectrum of agonist behaviors and how the SAR relates to biased agonism.
Compounds that represent different chemical space compared with that of the endogenous agonist have a greater propensity to engage and stabilize unique receptor conformations. Given the considerable structural differences between prototypical adenosine receptor (AR) ligands and the A 3 ARselective (N)-methanocarba derivatives, we hypothesized that these compounds may have a biased agonist profile relative to a reference A 3 AR agonist. The present study has quantified the bias profile of a number of prototypical A 3 AR agonists ( Fig. 1 ) alongside a series of (N)-methanocarba 59-N-methyluronamide nucleoside derivatives with modifications at the N 6 and C2 position (Fig. 2) . Furthermore, the current study explored the SAR of the (N)-methanocarba derivatives with respect to their bias profile, thereby aiding the rational design of future biased A 3 AR agonists. We attribute the observed biased agonism favoring cytoprotection to the C2 group extension from the orthosteric binding pocket toward transmembrane domain (TM) 2, which in turn stabilizes a different subset of A 3 AR conformations.
Materials and Methods
Materials. Fluo-4, Dulbecco's modified Eagle's medium (DMEM), and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, CA). Adenosine deaminase (ADA) and hygromycin-B were purchased from Roche (Basel, Switzerland). Fetal bovine serum (FBS) was purchased from ThermoTrace (Melbourne, Australia). AlphaScreen SureFire extracellular signal-regulated kinases 1 and 2 (ERK1/2), Akt 1/2/3, and cAMP kits were from PerkinElmer (Boston, MA). All compounds prefixed with MRS were synthesized as described previously (Tosh et al., 2012a,b) . All other reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture. The sequence of the human A 3 AR was cloned into the Gateway entry vector, pDONR201, and then transferred in the Gateway destination vector, pEF5/ FRT/V5-dest, using methods described previously (Stewart et al., 2009) . A 3 -FlpIn-CHO cells were generated using methods described previously (May et al., 2007) and maintained at 37°C in a humidified incubator containing 5% CO 2 in DMEM supplemented with 10% FBS and the selection antibiotic hygromycin-B (500 mg/ml). For cell survival, ERK1/2 phosphorylation, Akt 1/2/3 phosphorylation, and calcium mobilization assays, cells were seeded into 96-well culture plates at a density of 4 Â 10 4 cells/ well. After 6 hours, cells were washed with serum-free DMEM and maintained in serum-free DMEM for 12-18 hours at 37°C in 5% CO 2 before assaying. For cAMP assays, cells were seeded into 96-well culture plates at a density of 2 Â 10 4 cells/well and incubated overnight at 37°C in 5% CO 2 prior to assay.
Cell Survival Assays. Media were removed and replaced with HEPES-buffered saline solution (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 146 mM NaCl, 10 mM D-glucose, 5 mM KCl, 1mM MgSO 4 , 1.3 mM CaCl 2 , and 1.5 mM NaHCO 3 , pH 7.45) containing ADA (1 U/ml) and penicillin-streptomycin (0.05 U/ml) in the absence and presence of A 3 AR ligands. Plates were then maintained at 37°C in a humidified incubator for 24 hours, after which 5 mg/ml propidium iodide was added to cells. Plates were then read on an EnVision plate reader (PerkinElmer), with excitation and emission set to 320 nm and 615 nm, respectively. Data were normalized to 100% cell survival and 0% cell survival, determined at t 5 0 hours in HEPES buffer and t 5 24 hours in Milli-Q water, respectively.
ERK1/2 and Akt 1/2/3 Phosphorylation Assays. A concentrationresponse curve of ERK1/2 and Akt 1/2/3 phosphorylation for each ligand was performed in serum-free DMEM containing 1 U/ml ADA (5-minute exposure at 37°C). Agonist stimulation was terminated by removal of media and the addition of 100 ml of SureFire lysis buffer to each well. Plates were then agitated for 5 minutes. Detection of pERK1/2 involved an 80:20:120:1:1 v/v/v/v/v dilution of lysate: activation buffer: reaction buffer: AlphaScreen acceptor beads: AlphaScreen donor beads in a total volume of 11 ml in a 384-well ProxiPlate. Plates were incubated in the dark at 37°C for 1 hour followed by measurement of fluorescence by an EnVision plate reader (PerkinElmer) with excitation and emission set to 630 nm and 520-620 nm, respectively. Detection of Akt 1/2/3 phosphorylation involved a 40:9.8:39.2:1 v/v/v/v dilution of lysate: activation buffer: reaction buffer: AlphaScreen acceptor beads in a total volume of 9 ml in a 384-well Proxiplate. Plates were incubated in the dark at room temperature for 2 hours, after which a 19:1 v/v dilution of dilution buffer: AlphaScreen donor beads was added in a total volume of 11 ml. Plates were incubated at room temperature for a further 2 hours, followed by measurement of fluorescence by an EnVision plate reader (PerkinElmer) with excitation and emission set to 630 nm and 520-620 nm, respectively. Agonist concentration-response curves were normalized to the phosphorylation mediated by 10% FBS (5-minute stimulation).
Calcium Mobilization Assays. Media were removed from 96-well plates and replaced with HEPES-buffered saline solution containing 1 U/ml ADA, 2.5 mM probenecid, 0.5% bovine serum albumin (BSA), and 1 mM Fluo4. Plates were incubated in the dark for 1 hour at 37°C in a humidified incubator. A FlexStation plate reader (Molecular Devices, Sunnyvale, CA) performed the addition of HEPES-buffered saline solution in the absence and presence of agonist and measured fluorescence (excitation, 485 nm; emission, 520 nm) every 1.52 seconds for 75 seconds. The difference between the peak and baseline fluorescence was measured as a marker for intracellular Ca 21 mobilization. A 3 AR agonist concentration-response curves were normalized to the response mediated by 100 mM ATP to account for differences in cell number and loading efficiency.
Inhibition of cAMP Accumulation Assays. Media were replaced with a stimulation buffer (140 mM NaCl, 5 mM KCl, 0.8 mM MgSO 4 , 0.2 mM Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 1.3 mM CaCl 2 , 5.6 mM D-glucose, 5 mM HEPES, 0.1% BSA, 1 U/ml ADA, and 10 mM rolipram, pH 7.45) and incubated at 37°C for 1 hour. Inhibition of cAMP accumulation was assessed by preincubation of A 3 -FlpIn-CHO cells with A 3 AR agonists for 10 minutes, after which 3 mM forskolin was added for a further 30 minutes. The reaction was terminated by rapid removal of buffer and addition of 50 ml ice-cold 100% ethanol. Ethanol was allowed to evaporate before the addition of 50 ml detection buffer (0.1% BSA, 0.3% Tween-20, 5 mM HEPES, pH 7.45). Plates were agitated for 10 minutes, after which 10 ml lysate was transferred to a 384-well Optiplate. Detection involved addition of a 5 ml 1:49 v/v dilution of AlphaScreen acceptor beads: stimulation buffer. Following this, a 15 ml 1:146:3 v/v/v dilution of AlphaScreen donor beads: detection buffer: 3.3 U/ml biotinylated cAMP to form a total volume of 30 ml. The donor bead/biotinylated cAMP mixture was equilibrated for 30 minute prior to addition. Plates were incubated overnight in the dark at room temperature, followed by measurement of fluorescence by an EnVision plate reader (PerkinElmer) with excitation and emission set to 630 nm and 520-620 nm, respectively. Agonist concentrationresponse curves were normalized to the response mediated by 3 mM forskolin (0%) or buffer (100%) alone.
Molecular Modeling. Docking simulations were performed for all the compounds investigated in this study using homology models of (Tosh et al., 2012a,b) . the human A 3 AR (Supplemental Material, Data 1-3). In particular, three previously reported models were used: a model entirely based on an agonist-bound hA 2A AR crystal structure (PDB ID: 3QAK), a model based on a hybrid A 2A AR-b 2 adrenergic receptor template, and a model based on a hybrid A 2A AR-opsin template (b 2 adrenoceptor X-ray structure PDB ID: 3SN6; opsin crystal X-ray crystal structure PDB ID: 3DQB) (Tosh et al., 2012a) . Models based on hybrid templates show an outward movement of TM2 compared with the A 2A AR-based model. Structures of A 3 AR ligands were built and prepared for docking using the Builder and the LigPrep tools implemented in the Schrödinger suite (Schrödinger Release 2013 -3, Schrödinger, LLC, New York, NY, 2013 . Molecular docking of the ligands at the A 3 AR models was performed by means of the Glide package part of the Schrödinger suite. In particular, a Glide Grid was centered on the centroid of some key residues of the binding pocket of adenosine receptors, namely, Phe (EL2), Asn (6.55), Trp (6.48), and His (7.43). The Glide Grid was built using an inner box (ligand diameter midpoint box) of 14 Å Â 14 Å Â 14 Å and an outer box (box within which all the ligand atoms must be contained) that extended 25 Å in each direction from the inner one. Docking of ligands was performed in the rigid binding site using the XP (extra precision) procedure. The top scoring docking conformations for each ligand were subjected to visual inspection and analysis of protein-ligand interactions to select the proposed binding conformations in agreement with the experimental data.
Data Analysis. Statistical analyses and curve fitting were performed using Prism 6 (GraphPad Software, San Diego, CA). To quantify signaling bias, agonist concentration-response curves were analyzed by nonlinear regression using a derivation of the Black-Leff operational model of agonism, as described previously (Kenakin et al., 2012; Wootten et al., 2013; van der Westhuizen et al., 2014) . The transduction coefficient, t/K A [expressed as a logarithm, Log (t/K A )], was used to quantify biased agonism. To account for cell-dependent effects on agonist response, the transduction ratio was normalized to the values obtained for the reference agonist, IB-MECA, to generate DLog(t/K A ). To determine the bias for each agonist at different signaling pathways, the DLog(t/K A ) was normalized to a reference pathway, pERK1/2, to generate DDLog(t/K A ). Bias is defined as 10 DDLog(t/KA) where a lack of bias will result in values that are not statistically different from 1, or 0 when expressed as a logarithm. All results are expressed as the mean 6 S.E.M. Statistical analyses involved an F test or a one-way analysis of variance with a Tukey or Dunnett's post hoc test as referred to within Results, with statistical significance determined as P , 0.05.
Results
Agonist-Mediated Signal Transduction in FlpIn-CHO Cells Stably Expressing the Human A 3 AR. Quantification of agonist function at multiple intracellular signaling pathways is a requirement to investigate biased agonism. The A 3 AR preferentially couples to G i/o proteins, and therefore agonist activation stimulates the canonical signal transduction pathway, inhibition of adenylate cyclase activity (Fredholm et al., 2001 ). However, in addition to G i/o -adenylate cyclase coupling, A 3 ARs can also modulate a number of additional G protein-dependent and G protein-independent intracellular signaling pathways (Schulte and Fredholm, 2002; Fossetta et al., 2003; Merighi et al., 2006; Gao and Jacobson, 2008) . In this study, agonists were assessed for their ability to inhibit cAMP accumulation, phosphorylate ERK1/2 and Akt(Ser473) 1/2/3, increase intracellular calcium concentrations and promote cytoprotection. Previous studies have established that the (N)-methanocarba derivatives used within the current study have low nanomolar affinity for the high-affinity G protein-coupled state of the human A 3 AR, with the exception of the pyrene-containing compounds, MRS5704 and MRS5783 (Fig. 2) , which have affinities in the micromolar range (Tosh et al., 2012a,b) . Furthermore, previous studies have demonstrated that, with the exception of MRS5704 and MRS5776, these compounds confer an equivalent level of inhibition of cAMP accumulation to the nonselective AR agonist 59-(N-ethylcarboxamido) adenosine (NECA) and therefore are high efficacy agonists at the human A 3 AR (Tosh et al., 2012a,b) .
A concentration-dependent inhibition of 3 mM forskolinstimulated cAMP accumulation in Chinese hamster ovary FlpIn cells stably expressing the human A 3 AR (A 3 -FlpIn-CHO) was observed for the prototypical A 3 AR agonists, IB-MECA, 2-(1-hexynyl)-N-methyladenosine (HEMADO), NECA, and Fig. 3) were observed for prototypical A 3 AR agonists and (N)-methanocarba 59-Nmethyluronamide nucleoside derivatives. Compared to the reference agonist IB-MECA, most agonists behaved as full agonists, with the exception of MRS5655, MRS5916, MRS7030, and MRS7034, which stimulated a partial response for pERK1/2, and AB-MECA, MRS5679 and MRS5916, which stimulated a partial response for Akt 1/2/3 phosphorylation (Table 2) . A concentration-dependent increase in intracellular calcium mobilization was observed for each agonist assessed (Table 1 ; Supplemental Fig. 4 ). Full agonism was observed for most of the agonists, with the exception of MRS5679, which behaved as a partial agonist (Table 2) . Endogenously expressed A 3 ARs can promote the survival of a number of different cell types (Matot et al., 2006; Headrick and Lasley, 2009; Survival IB-MECA 9.6 6 0.1 9.4 6 0.1 8.9 6 0.2 8.9 6 0.4 9.2 6 0.2 NECA 8.6 6 0.1 8.3 6 0.1 7.6 6 0.2 8.2 6 0.1 8.3 6 0.3 HEMADO 9.4 6 0.1 9.3 6 0.1 8.1 6 0.2 9.3 6 0.2 9.1 6 0.3 AB-MECA 8.1 6 0.1 7.6 6 0.2 7.5 6 0.2 7.9 6 0.3 8.1 6 0.2 MRS3558 9.8 6 0.1 9.6 6 0.1 8.8 6 0.2 8.5 6 0.3 10.2 6 0.2 MRS5655 9.3 6 0.1 9.1 6 0.1 8.3 6 0.2 7.5 6 0.3 9.7 6 0.2 MRS5667 8.1 6 0.1 8.5 6 0.2 8.2 6 0.1 7.6 6 0.1 9.9 6 0.2 MRS5679 7.6 6 0.1 8.1 6 0.1 6.6 6 0.4 6.7 6 0.4 9.6 6 0.2 MRS5698 8.1 6 0.1 8.3 6 0.1 8.1 6 0.1 7.8 6 0.1 9.5 6 0.2 MRS5704 6.2 6 0.1 6.7 6 0.1 5.8 6 0.1 5.4 6 0.2 7.9 6 0.2 MRS5776 7.8 6 0.1 6.8 6 0.7 NA NA 8.3 6 0.4 MRS5783 6.0 6 0.1 6.5 6 0.1 5.9 6 0.1 5.5 6 0.1 7.7 6 0.1 MRS5857 9.7 6 0.1 9.1 6 0.1 8.8 6 0.2 7.7 6 0.4 9.9 6 0.2 MRS5916 9.5 6 0.1 9.5 6 0.1 9.2 6 0.1 8.3 6 0.1 9.5 6 0.3 MRS7030 8.1 6 0.1 8.8 6 0.1 7.9 6 0.1 7.2 6 0.1 8.4 6 0.3 MRS7034 8.0 6 0.1 9.4 6 0.1 7.8 6 0.1 7.6 6 0.2 9.2 6 0.2 CHO, Chinese hamster ovary; NA, no detectable response.
Biased Agonism at the Adenosine A 3 Receptor 2013). In our heterologous expression system, the ability of A 3 AR agonists to increase cell viability after 24 hours of serum starvation was assessed using propidium iodide, which stains the nuclear matter of cells with a compromised plasma membrane (Kepp et al., 2011) . A 3 -FlpIn-CHO cell viability was decreased by approximately 40% after 24-hour serum starvation. Exposure of cells to either prototypical A 3 AR agonists or the (N)-methanocarba 59-N-methyluronamide nucleoside derivatives mediated a robust concentration-dependent increase in cell survival, increasing the percentage of viable cells from 60% to approximately 85% (Tables 1 and Table 2 ; Supplemental Fig. 5) . A similar maximal effect to the reference agonist IB-MECA was observed for each agonist assessed with the exception of MRS5916, MRS7030, and MRS7034 that mediated a partial response, increasing cell survival to approximately 75% ( Table 2) . The 49-truncated (N)-methanocarba derivative MRS5776 has previously been suggested to act as a low-efficacy partial agonist (Tosh et al., 2012b) . Consistent with these findings, at signaling pathways assessed in the current study, MRS5776 stimulated either no detectable response (Akt 1/2/3 phosphorylation and calcium mobilization) or behaved as a weak partial agonist (inhibition of cAMP accumulation, ERK1/2 phosphorylation, and cell survival) ( Tables 1 and Table 2 ).
Biased Signaling Profile of A 3 AR Ligands. The concept of biased agonism arose from experimentally observed variations in the relative potency or maximal effect upon stimulation of different intracellular signaling pathways in a manner that could not be explained by simple differences in the coupling efficiency of intracellular effectors within a particular cell background (Kenakin et al., 2012) . Changes in the relative potency, and indeed the rank order of potency, were observed for the (N)-methanocarba 59-N-methyluronamide nucleoside derivatives relative to the reference agonist, IB-MECA (Table 1 ). The rank order of potency of the reference agonist IB-MECA was ERK1/2 phosphorylation . inhibition of cAMP accumulation . cell survival . Akt 1/2/3 phosphorylation 5 calcium mobilization (Fig. 3A) . In contrast, the highest potency for C2 extended compound MRS5679, relative to all other signaling pathways assessed, was cell survival (Fig. 3B) . Furthermore, the N 6 -modified compound MRS7034 had a similar potency for inhibition of cAMP accumulation and cell survival but lower potency for ERK1/2 phosphorylation, Akt 1/2/3 phosphorylation and calcium mobilization (Fig. 3C) . These are two examples of changes in relative potencies causing a change in the rank order of agonist potency. For two compounds, differential partial agonism across the different signaling endpoints was observed. The N 6 unsubstituted compound, MRS5916, is a partial agonist for stimulating ERK1/2 phosphorylation and cell survival but a full agonist with respect to calcium mobilization (Table 2 ). In contrast, N 6 substituted MRS5679, which is highly extended with a biarylethynyl group at C2, is a partial agonist for stimulating calcium mobilization but a full agonist for ERK1/2 phosphorylation and cell survival ( Fig. 3B; Table 2 ). Collectively, these results demonstrate that a number of the (N)-methanocarba 59-N-methyluronamide nucleoside derivatives display biased agonism relative to the reference agonist IB-MECA.
An extension to the Black-Leff operational model was used to quantify bias (Kenakin et al., 2012) . Transduction coefficients, Log(t/K A ), for each ligand at each pathway assessed were estimated from concentration-response data. To account for system bias, the Log(t/K A ) value was normalized to the reference agonist IB-MECA to generate DLog(t/K A ) (Table 3) . To minimize the propagation of error, statistical analysis interrogating significant differences in the signaling was assessed using the DLog (t/K A ) value. Relative to IB-MECA, the prototypical agonists NECA, HEMADO, and AB-MECA display no significant bias at any of the pathways assessed (Fig. 4A) . In contrast, a number of compounds in the (N)-methanocarba series exhibited significant bias at one or more of the pathways investigated. With the exception of MRS3558, each of the (N)-methanocarba 59-Nmethyluronamide N 6 -(3-chlorobenzyl) nucleoside derivatives had significant bias toward cell survival relative to at least one other pathway (Fig. 4B) . The bias profile for the (N)-methanocarba 59-N-methyluronamide nucleoside derivatives with additional N 6 modifications was more complex, with compounds possessing bias toward cell survival, away from calcium mobilization and/or toward cAMP accumulation (Fig. 4C) . The effect of 49-truncation on signaling bias was not determined as MRS5776 had minimal activity at most of the signaling intermediates assessed ( Table 2) .
The DLog(t/K A ) values were then normalized to a reference pathway, pERK1/2, to generate DDLog(t/K A ) values (Table 3) . In addition to accounting for the system bias, the DDLog(t/K A ) value, referred to hereafter as the Log (bias factor), also accounts for differences in agonist efficacy. To better conceptualize and visualize the data, bias factors were plotted on a "web of bias." The web of bias clearly demonstrates that, relative to IB-MECA, the prototypical agonists NECA, HEMADO, and AB-MECA display no bias as evidenced by each of the values approximating to 1 (Fig. 5A) . In contrast, a number of compounds in the (N)-methanocarba series exhibit bias toward cell survival, away from calcium mobilization or toward the inhibition of cAMP accumulation (Fig. 5, B and C) . -(3-chlorobenzyl) derivatives with different C2 substituents (B) and (N)-methanocarba derivatives with different N 6 modifications (C) for ERK1/2 phosphorylation, inhibition of cAMP accumulation, Akt 1/2/3(Ser473) phosphorylation, intracellular calcium mobilization and cell survival in A 3 -FlpIn-CHO cells. *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 one-way analysis of variance; Tukey's multiple comparisons. Data points represent the mean 6 S.E.M. of three tonine separate experiments conducted in duplicate. Error bars not shown lie within the dimensions of the symbol.
Collectively, these data establish that a number of the conformationally constrained (N)-methanocarba 59-N-methyluronamide nucleoside derivatives have significant bias, relative to IB-MECA, and suggest that one or more of their distinct structural features may have a role in promoting the divergent signaling profile observed.
To assess the SAR of the bias profiles, the length (in Å) of the C2 and N 6 substituents of the (N)-methanocarba 59-Nmethyluronamide nucleoside derivatives were compared with the bias detected. The bias conferred upon varying the N 6 substituent was complex, and no clear relationship was evident. In contrast, there was a significant positive relationship between the length of the C2 substituent and the cell survival Log (bias factor) for compounds with an N 6 -(3-chlorobenzyl) substituent (r 2 5 0.92, P , 0.05). That is, increasing the length of the C2 substituent increased the bias toward cell survival (Fig. 5D) . Importantly, A 3 AR ligands had no effect on cell survival in nontransfected FlpIn-CHO cells, confirming that the bias identified was downstream of the A 3 AR (Supplemental Fig. 6 ). As such, these data have identified a key constituent on (N)-methanocarba 59-N-methyluronamide nucleoside derivatives that can promote bias at the A 3 AR toward increased cell survival.
Docking into A 3 AR Homology Models. Molecular modeling was used to facilitate the understanding of the relationship between the length of the C2 substituent and bias observed at the A 3 AR. To date, there are no available crystallographic structures of the human A 3 AR; however, several crystal structures of the human A 2A AR in complex with both agonists and antagonists have been reported (Jaakola et al., 2008; Doré et al., 2011; Xu et al., 2011) , highlighting the key interactions for ligand binding at the adenosine receptor family. Previous studies have suggested that homology models of the human A 3 AR, based on the human A 2A AR, cannot accommodate (N)-methanocarbasubstituted compounds with rigid elongated C2 substituents in an orientation that would form key interactions with residues of the binding site. Instead, docking of such derivatives required models based on a hybrid A 2A AR-b 2 adrenergic Fig. 5 . 'Web of bias' for A 3 AR agonists. The bias profile of prototypical A 3 AR agonists (A), (N)-methanocarba N 6 -(3-chlorobenzyl) derivatives with different C2 substituents (B) and (N)-methanocarba derivatives with different N 6 modifications (C) can be visualized on a "web of bias." The web of bias plots bias factor for each ligand and for every signaling pathway tested. Bias factors have been normalized to the reference ligand, IB-MECA, and the reference pathway, ERK1/2 phosphorylation. Linear regression analysis (D) identified a significant positive relationship with respect to agonist C2 length (Å) and bias toward cell survival for compounds with an N receptor template or a hybrid A 2A AR-opsin template where TM2 is shifted outward from the binding site (Tosh et al., 2012a) . Similarly, in the present study these hybrid models were used to dock the (N)-methanocarba 59-N-methyluronamide nucleoside derivatives with extended C2 substituents (Supplemental Material, Data 1-3). In particular, MRS3558 fit the A 3 AR model based entirely on the human A 2A AR, MRS5655, and MRS5698 required the hybrid A 2A AR-b 2 receptor model, whereas MRS5679, MRS5704, and MRS5783 required the hybrid A 2A AR-opsin model (Fig. 6) . Therefore, the extension of the C2 substituent seems to be correlated with a progressive shift of TM2 outward from the binding site that is likely to promote the stabilization of a unique subset of A 3 AR conformations responsible for biased activation.
The effect of the C2 substituent on receptor conformation seems to be modulated also by the N 6 group of the ligand. This substituent is accommodated in a mainly hydrophobic region delimited by the second extracellular loop and can have an effect in determining the overall conformation of the receptor explaining why the bias pattern changes for compounds bearing the same C2 group but different N 6 substituents. Furthermore, the (N)-methanocarba ring of the studied nucleoside derivatives forces the pseudo-sugar moiety into a North-envelope conformation and thereby constrains the orientation of the interactions with key residues in the lower part of the binding site, including Thr94 in TM3 and Ser271 and His272 in TM7, known to be important in receptor activation (interactions not formed in antagonist-bound structures) (Jaakola et al., 2008; Xu et al., 2011) . This constrained conformation could also be responsible for the bias of (N)-methanocarba derivatives, relative to the reference agonist IB-MECA.
Discussion
The emerging paradigm of GPCR biased agonism has become an increasingly important concept in modern drug discovery. The SAR of biased agonism has been investigated previously at a number of GPCRs, including the AT 1 R and dopamine D 2 receptors (Holloway et al., 2002; Chen et al., 2012; Shonberg et al., 2013) ; however, bias at the A 3 AR remains a relatively new concept (Gao and Jacobson, 2008) . The current study took advantage of the rich SAR surrounding the A 3 AR to gain insights into the structural determinants that govern bias at this receptor. We investigated the signaling profile of a series of (N)-methanocarba substituted derivatives, which have a relatively rigid conformation, in addition to prototypical A 3 AR agonists, and correlated the observed patterns with proposed structural plasticity of the A 3 AR (Tosh et al., 2012a,b) . Relative to the reference agonist IB-MECA, the prototypical A 3 AR agonists NECA, HEMADO, and AB-MECA, which all contain flexible ribose rings, did not display biased signaling at any of the five signaling pathways investigated. In contrast, a number of the structurally distinct (N)-methanocarba derivatives displayed significant bias, relative to IB-MECA, for cell survival signaling, intracellular calcium mobilization, and/or inhibition of cAMP accumulation. Moreover, this study has identified the C2 group of (N)-methanocarba 59-N-methyluronamide nucleoside agonists as a key determinant for signaling bias toward cell survival.
As there is no X-ray crystallographic structure of the A 3 AR, homology modeling of the human A 3 AR can facilitate the interpretation of SAR studies for (N)-methanocarba nucleosides. Within the A 2A AR crystal structure, nonconserved disulphide bonds constrain the extracellular portion of TM2 toward the TM bundle (Tosh et al., 2012b) . However, docking of rigid (N)-methanocarba 59-N-methyluronamide nucleoside derivatives with elongated C2 substituents at the A 3 AR model required a significant outward movement of TM2 to maintain conserved polar contacts surrounding the ribose and adenine moieties. As such, these compounds were better accommodated using a hybrid A 2A AR-b 2 adrenergic receptor template or an A 2A AR-opsin template, which have an approximate 4 Å and 7 Å outward movement of the extracellular portion of TM2 at the Ca atom of Ser73, respectively (Tosh et al., 2012b) . These findings highlight the significant conformational changes that are likely to occur upon binding of biased A 3 AR agonists.
Although residues of TM2 are not predicted to be directly involved in binding of prototypical A 3 AR agonists, this transmembrane domain has been suggested previously to play an important role in modulating ligand binding and receptor activation. Mutagenesis studies at the A 1 AR and A 3 AR suggest residues within TM2 govern the negative allosteric modulation observed for sodium on agonist binding (Barbhaiya et al., 1996; Gao et al., 2003) . This hypothesis was recently validated by the high-resolution antagonist-bound A 2A AR crystal structure that identified the highly conserved aspartate residue in TM2, Asp 2.50 as a key residue within the sodium-binding pocket (Liu et al., 2012) . Furthermore, TM2 is involved in a water-mediated hydrogen bond network with TM1, TM6, and TM7, which has been suggested to regulate GPCR activation (Rosenkilde et al., 2010; Nygaard et al., 2010) . Our data suggest that the altered conformation, stabilized in the presence of rigid (N)-methanocarba 59-Nmethyluronamide nucleoside derivatives with elongated C2 substituents, may contribute to cytoprotective signaling in A 3 -FlpIn-CHO cells.
Although this study found a clear relationship between C2 length and cell survival, there was no accompanying preferential coupling to the ERK1/2 and Akt 1/2/3 phosphorylation pathways, which have been implicated in promoting cell survival in a number of settings (Wada and Penninger, 2004; Manning and Cantley, 2007) . This suggests that the conformations induced by these ligands may give rise to protective signaling that is independent of these protein kinases and/or represents compartmentalized signaling that was not detected using the methods employed. Of particular interest for future studies would be to investigate the ability of the different classes of ligands to couple to G protein-independent pathways, such as b-arrestin recruitment, as this has been shown to play an important role in A 3 AR signaling (Gao and Jacobson, 2008) . The ability of A 3 AR agonists to stimulate b-arrestin recruitment will also influence subsequent A 3 AR desensitization and/or internalization. These time-dependent processes are an important consideration, as signaling assays require different incubations times and therefore may be differentially influenced by A 3 AR desensitization and/or internalization. Future studies will also assess the binding kinetics of structurally distinct A 3 AR agonists, as it is becoming appreciated that the agonist residence time can influence the efficacy and bias profile observed (Sykes et al., 2009; Guo et al., 2012; Klein Herenbrink, 2016) .
This study has found a clear relationship between C2 length of (N)-methanocarba substituted derivatives and ligand bias; however, also of interest is the SAR pertaining to modifications at the N 6 position. MRS5655 and MRS5916 differ only by their N 6 substituent; MRS5655 contains a 3-chlorobenzyl and MRS5916 a primary amine group. Interestingly, although N 6 unsubstituted MRS5916 displayed no significant bias, the corresponding N 6 -(3-chlorobenzyl) analog MRS5655 had significant bias toward cell survival relative to calcium. However, a further elongated N 6 substituent in MRS5857 produced equivalent activities in cell survival and calcium. Similarly, the structures of highly C2-extended MRS5679 and MRS5667 differ only by their N 6 substituents; MRS5679 has a 3-chlorobenzyl group, whereas MRS5667 has a methyl group. Both compounds are biased toward cell survival relative to all pathways; however, MRS5667 has additional bias toward cAMP and therefore a slightly different signaling fingerprint from that of MRS5679. The degree of bias can also be influenced by subtle changes in agonist structure. At a qualitative level, the N 6 stereoisomers, MRS7030 and MRS7034, show the same bias profile; however, whereas MRS7030 has an approximately 6-fold bias toward cell survival and cAMP, greater effects are observed for MRS7034, with this compound having approximately 28-fold and 23-fold bias toward cell survival and cAMP, respectively. Collectively, these findings indicate that the N 6 substituent, which interacts with extracellular regions of the A 3 AR, is likely to play an important role in driving A 3 AR signal transduction and signaling bias. Furthermore, it is clear that the SAR surrounding A 3 AR biased agonism is multifactorial and likely to involve interactions with a number of residues within and outside the binding pocket that can be influenced by one or more chemical modifications. Some structural differences did not alter the signaling profile; for example, 1-and 4-pyrene isomers, MRS5704 and MRS5783, respectively, displayed the same profile. The effect of 49-truncation on signaling bias could not be determined because truncated MRS5776 was inactive at a number of the pathways assessed.
As a pharmacologic paradigm, biased agonism can provide significant advantages in situations where both the desired effects and adverse effects are activated downstream of the same target. A 1 AR-biased agonism has been previously investigated (Langemeijer et al., 2013; Valant et al., 2014; Baltos et al., 2016) and recently demonstrated to allow for the selective stimulation of cardioprotective signal transduction in the absence of the adverse hemodynamic effects commonly associated with A 1 AR therapies (Valant et al., 2014) . The current study has identified a range of bias profiles for subtype selective A 3 AR agonists, which offer a potential therapeutic advantage. Importantly, these bias profiles must be validated in relevant endogenous systems to understand the system dependence of the signaling fingerprints and therefore better gauge the therapeutic potential. However, if similar bias profiles were observed within the cell type of interest, the discovery of biased cytoprotective compounds may have clinical implications when targeting the A 3 AR. A 3 AR activation is protective in cardiac and lung ischemiareperfusion injury and can prevent glaucoma-induced cell death (Matot et al., 2006; Headrick and Lasley, 2009; Fishman et al., 2013) . Paradoxically, although low concentrations of A 3 AR agonists stimulate pro-survival signaling, high concentrations promote apoptosis (Jacobson, 1998) . Therefore, A 3 AR agonists that preferentially couple to pro-survival pathways may promote A 3 AR-mediated cell survival in the absence of apoptotic signal transduction. The A 3 AR is also a potential target for the treatment of hepatocellular carcinoma, with an A 3 AR agonist currently in clinical trials (Fishman et al., 2012) . In cancerous cells, A 3 AR activation promotes apoptosis and decreases proliferation through stimulation of G i/o proteins, which decreases the protein kinase A-mediated inhibition of GSK-3b. GSK-3b destabilizes Wnt signal transduction, an important pathway for proliferation and cell-cycle progression (Fishman et al., 2002; Bar-Yehuda et al., 2008) . As such, agonists such as MRS5667, MRS7030, and MRS7034, which display bias toward the inhibition of cAMP accumulation, may be of relevance in the treatment of hepatocellular carcinoma.
This study highlights the importance of rigorously assessing the signaling profile of lead compounds intended for future clinical use. High-throughput screening at a single endpoint is necessary for rapid assessment of novel chemical entities; however, this method provides only a snapshot of the full signaling repertoire and therefore is unable to identify biased agonists. Through profiling at multiple signaling pathways, this study has identified a number of A 3 AR biased agonists. Furthermore, we have informed, for the first time, the SAR surrounding A 3 AR biased agonism, particularly with respect to the observed bias toward cell survival. An understanding of the SAR involved in conferring A 3 AR biased agonism will allow for the rational design of novel A 3 AR therapeutics that can fine-tune the downstream signal transduction and therefore enhance the observed clinical efficacy.
